WuXiHigh 2.0 Delivers A 180 mg/mL Formula

High‑concentration biologics are essential for enabling subcutaneous dosing, reducing patient burden, and supporting self‑administration — but achieving the required stability and viscosity at elevated concentrations is often a formidable technical barrier. This case study follows a CNS‑focused biopharmaceutical company that needed to transition a monoclonal antibody from an IV format to a subcutaneous option, requiring a dramatic increase from 50 mg/mL to 180 mg/mL while maintaining solubility, manufacturability, and a viscosity below 20 cP.

The narrative highlights the scientific and operational complexities that arise as protein concentration climbs, including purification challenges during UF/DF, viscosity spikes, and the need for rapid development to keep clinical timelines on track. It also outlines how advanced screening, excipient optimization, and integrated CMC collaboration enabled a stable formulation suitable for delivery through a 5 mL prefilled syringe.

For teams working to adapt existing biologics for patient‑friendly delivery formats or exploring high‑concentration product strategies, the case study offers a clear look at how thoughtful design and coordinated development can efficiently overcome these hurdles.